Welcome to our dedicated page for PepGen news (Ticker: PEPG), a resource for investors and traders seeking the latest updates and insights on PepGen stock.
PepGen Inc. (PEPG) is a clinical-stage biotechnology pioneer developing next-generation oligonucleotide therapies for severe neuromuscular and neurological disorders. This page provides investors and industry observers with timely updates on the company's proprietary EDO platform advancements, clinical trial progress, and strategic initiatives.
Access consolidated information on key developments including regulatory milestones, research collaborations, and pipeline updates for candidates like PGN-EDO51 (Duchenne muscular dystrophy) and PGN-EDODM1 (myotonic dystrophy). Our news collection serves as a definitive resource for tracking the company's progress in overcoming oligonucleotide delivery challenges through engineered peptide technology.
Discover updates across three core areas: clinical trial results demonstrating therapeutic potential, peer-reviewed research validating the EDO platform's mechanisms, and strategic partnerships accelerating therapeutic development. All content is curated to help stakeholders monitor PepGen's progress in addressing critical unmet needs in genetic medicine.
Bookmark this page for streamlined access to PEPG's latest verified developments. Check regularly for updates on novel therapeutic approaches targeting muscle and central nervous system disorders through enhanced oligonucleotide delivery systems.
PepGen Inc. (Nasdaq: PEPG) announced positive clinical data from the first dose cohort (5 mg/kg) of PGN-EDO51, its lead candidate for Duchenne muscular dystrophy (DMD) patients amenable to exon 51-skipping. In the CONNECT1-EDO51 Phase 2 trial, PGN-EDO51 showed:
- Mean exon skipping levels of 2.15% after three months
- Mean muscle-adjusted dystrophin level of 1.49%, a 0.70% increase from baseline
- Mean absolute dystrophin level of 0.61%, a 0.26% increase from baseline
The 5 mg/kg dose was well-tolerated, with all patients continuing to the long-term extension. Dosing of the second cohort at 10 mg/kg is ongoing. PepGen plans to optimize the design of the CONNECT2 Phase 2 trial based on these results.
PepGen has expanded its executive team with the appointments of Afsaneh Mohebbi, Ph.D., as Senior Vice President of Portfolio and Program Management, and Dave Borah, CFA, as Senior Vice President of Investor Relations and Corporate Communications. These appointments aim to strengthen PepGen's expertise as it prepares for significant clinical milestones in the second half of the year. Dr. Mohebbi brings extensive experience from her previous roles in biotech firms, including Agios Pharmaceuticals and Shire Human Genetic Therapies. She has a proven track record in advancing clinical candidates and managing cross-functional teams. Dave Borah, CFA, comes with over 20 years of experience in investor relations and corporate communications, having served at Mural Oncology and Bicycle Therapeutics. His background includes successful equity raises and increased analyst coverage, making him a valuable addition to PepGen's strategic communications efforts.
PepGen, a clinical-stage biotechnology company, announced two executive promotions. Michelle Mellion, M.D., is now Chief Medical Officer, and Hayley Parker, Ph.D., is the new Senior Vice President of Global Regulatory Affairs. These promotions highlight their significant contributions to PepGen's clinical and regulatory strategies. Mellion has been pivotal in advancing the company's neuromuscular programs and has a rich background in clinical development and neurology. Parker has been essential in shaping PepGen's global regulatory strategy, bringing extensive experience in regulatory affairs and rare diseases. These leadership changes aim to bolster PepGen's efforts in developing innovative oligonucleotide therapies for severe neuromuscular and neurological diseases.
PepGen (Nasdaq: PEPG), a clinical-stage biotech company, reported its Q1 2024 financial results and recent corporate highlights. Key points include the expected mid-2024 preliminary data from the CONNECT1-EDO51 trial and second half 2024 data from the FREEDOM1-DM1 trial. PepGen raised $86.3 million from stock offerings, extending its cash runway into 2026. Research and Development expenses for Q1 2024 were $14.7 million, up from $14.4 million in Q1 2023, and General and Administrative expenses rose to $5.1 million from $3.7 million. The company reported a net loss of $18.0 million, compared to $16.3 million in Q1 2023. They had 32.4 million shares outstanding as of March 31, 2024.
FAQ
What is the current stock price of PepGen (PEPG)?
What is the market cap of PepGen (PEPG)?
